Children with nonalcoholic fatty liver disease (NAFLD) have a higher risk for type 2 diabetes (T2D), according to a study published in Clinical Gastroenterology and Hepatology.

Novo Nordisk NVO announced that the FDA has granted accelerated approval to its blockbuster GLP-1 drug, Wegovy (semaglutide 2 ...

D&D Pharmatech Announces Rapid, Clinically Significant Reductions in Liver Fat Achieved in Four Weeks Treating NAFLD Patients with DD01, a Novel Long-Acting GLP-1/Glucagon Receptor Agonist ...

MASLD rates have decreased, whereas liver fibrosis and cirrhosis rates have increased among US patients with type 2 diabetes since 2017.

New European guidelines redefine Metabolic dysfunction-associated steatotic liver disease (MASLD) care, offering clearer ...

The presence of T2D and obesity was the strongest risk factors for hepatic fibrosis in young adults (odds ratios, 4.33 and 1.16, respectively; P < .05 for both).

The drug received accelerated approval for use in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Coexisting T2D, obesity, and metabolic syndrome sharply increase the risk for myocardial infarction, stroke, kidney failure, and neuropathy. This cluster leads to severe health consequences and ...

The updated European guidelines for managing metabolic dysfunction-associated steatotic liver disease (MASLD) mark a ...

Data will be presented on Monday, November 18 th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego. LEGEND achieved ...